Original Research
Published on 26 Oct 2023
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
in Breast Cancer
Frontiers in Oncology
doi 10.3389/fonc.2023.1247270
- 8,583 views
- 4 citations
